Sunnyvale, California-based BioCardia, Inc. [Nasdaq: BCDA], a company specializing in the development of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced on May 9, 2023, that the United States Patent Office has awarded them Patent Number 11,642,377. The patent, titled “Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, will be in effect until 2039.
The patented technology pertains to the methods of selecting and expanding NK1R+ Mesenchymal Stem Cells (MSC) for therapeutic uses. These cells can be utilized for the treatment of various health conditions including cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. A total of eighteen claims have been authorized under this patent.
The company’s President and CEO, Dr. Peter Altman, has expressed that this development holds significant potential for the advancement of mesenchymal stem cell therapies. The company’s team discovered that Substance P (SP), a neuropeptide, plays a crucial role in defense, stress, repair, and survival systems.
The team then explored whether they could select and then expand mesenchymal stem cells that express the Neurokinin-1 (NK1) receptor, the primary receptor for SP on the surface of many cells. With the patent granted, BioCardia now possesses the exclusive rights in the U.S. to this promising therapeutic approach that could treat a wide array of diseases. The company intends to look for development partners beyond their current cardiopulmonary focus.
BioCardia’s existing therapeutic platforms include CardiAMP™ autologous and NK1R+ allogeneic cell therapies. These platforms are supporting the development of four product candidates. The CardiAMP Cell Therapy Heart Failure Trial investigational product has received Breakthrough designation by the FDA, has CMS reimbursement, and is financially backed by the Maryland Stem Cell Research Fund.
The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement. The company’s portfolio also includes the Helix™ Transendocardial Biotherapeutic Delivery System, which is selectively partnered with other biotherapeutic companies requiring local delivery to the heart.
Forward Looking Statements:
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to development and importance of NK1R+ expanded MSC, our statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Anne Laluc, Marketing